DPFS Devolved Portfolio (Pilot)

Lead Research Organisation: University of Edinburgh

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

This is an award of a devolved portfolio under a pilot phase, as part of the implementation of the Development Pathway Funding Scheme (DPFS). DPFS Devolved Portfolios are block awards for specific universities to support goal-orientated translational research projects. The award allows universities to allocate the money to different translational projects more responsively based on their relative progress. For example the university might decide to stop a particular project and recycle the money allocated to it into other proposals. All projects supported by the Portfolio fall within the remit of the Development Pathway Funding Scheme (DPFS).

Publications

10 25 50

publication icon
Hall RJ (2013) Delirium and cerebrospinal fluid S100B in hip fracture patients: a preliminary study. in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

publication icon
Hintersteiner M (2012) On-bead screens sample narrower affinity ranges of protein-ligand interactions compared to equivalent solution assays. in Chemphyschem : a European journal of chemical physics and physical chemistry

publication icon
O'Neill S (2012) The role of heat shock protein 90 in modulating ischemia-reperfusion injury in the kidney. in Expert opinion on investigational drugs

 
Description Cerebral Aging (New neuropsychological instrument for the diagnosis and monitoring of delirium)
Geographic Reach Asia 
Policy Influence Type Membership of a guidance committee
 
Description Imaging for Human Health Royal Society of Chemistry (Functional Optical Imaging in mice and man)
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a national consultation
 
Description MSc in Surgical Science (A pharmacological pre-conditioning agent to reduce organ injury in transplantation)
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Medical SAB (Functional Optical Imaging in mice and man)
Geographic Reach Asia 
Policy Influence Type Participation in advisory committee
Impact Advice to Mauna Kea technologise on implementation of probes into medical practice.
 
Description President of the European Delirium Association (New neuropsychological instrument for the diagnosis and monitoring of delirium
Geographic Reach Europe 
Policy Influence Type Participation in advisory committee
 
Description RSC (Functional Optical Imaging in mice and man)
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Scottish Delirium Association (New neuropsychological instrument for the diagnosis and monitoring of delirium)
Geographic Reach National 
Policy Influence Type Membership of a guidance committee
 
Description Surgical Science MSc (A pharmacological pre-conditioning agent to reduce organ injury in transplantation)
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description 5?-reduced glucocorticoids and angiogenesis (Abernethie A with Andrew R, Hadoke PWF, Walker BR)
Amount £140,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 08/2020
 
Description 5a-Tetrahydrocorticosterone (5aTHB); DPFS
Amount £850 (GBP)
Organisation Edocrine Societies 
Sector Public
Country United States
Start  
 
Description 5a-Tetrahydrocorticosterone (5aTHB); a pathway to a novel, safer, topical anti-inflammatory glucocorticoid (Andrew R, Walker BR, Webster SP
Amount £73,218 (GBP)
Organisation Wellcome Trust 
Department Wellcome Trust Institutional Strategic Support Fund
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Analytical Science Digital Signal Processing
Amount £11,600,000 (GBP)
Funding ID EP/K03197X/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 10/2016 
End 08/2018
 
Description BHF Studentship (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs))
Amount £120,000 (GBP)
Organisation University of Glasgow 
Department British Heart Foundation Unit
Sector Academic/University
Country United Kingdom
Start 10/2012 
End 09/2015
 
Description Clinical Research Fellowship EDTB2 delirium and stroke patients
Amount £230,000 (GBP)
Funding ID RTF17/0111 
Organisation The Dunhill Medical Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2012 
End 09/2015
 
Description DPAK GSK (KMO inhibitors)
Amount £1,300,000 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 10/2012 
End 10/2015
 
Description DPFS Dell App -Biomedical Catalyst
Amount £1,170,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2016 
End 12/2019
 
Description ERI IKTF TRPM8 hit discovery
Amount £12,500 (GBP)
Organisation University of Edinburgh 
Sector Academic/University
Country United Kingdom
Start 09/2012 
End 02/2013
 
Description Early Career Grant (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)
Amount £10,000 (GBP)
Organisation Society for Endocrinology 
Sector Learned Society
Country United Kingdom
Start  
 
Description Edinburgh BioQuarter Del Box
Amount £4,000 (GBP)
Funding ID GQ2353 
Organisation Scottish Enterprise 
Sector Public
Country United Kingdom
Start 04/2012 
End 08/2012
 
Description Edinburgh Delirium Test Centenary Award to Dr Zoe Tieges.
Amount £25,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 12/2016 
End 12/2018
 
Description Edinburgh Delirium Test Development and validation of the 4AT: a new rapid screening tool for delirium.
Amount £820,000 (GBP)
Organisation Medical Research Council (MRC) 
Department MRC National Institute for Medical Research (NIMR)
Sector Public
Country United Kingdom
Start 01/2016 
End 01/2020
 
Description Health Innovation Challenge Fund (Functional Optical Imaging in mice and man)
Amount £2,000,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2011 
End 08/2014
 
Description IKTF (TRPM8 agonist compound expansion)
Amount £12,500 (GBP)
Organisation University of Edinburgh 
Sector Academic/University
Country United Kingdom
Start 12/2012 
End 10/2013
 
Description IKTF (functional readout TRPM8 agonists)
Amount £15,000 (GBP)
Organisation University of Edinburgh 
Sector Academic/University
Country United Kingdom
Start 10/2012 
End 10/2013
 
Description Initiating Knowledge Transfer Fund (TRPM8 agonists as analgesics for chronic neuropathic pain)
Amount £7,600 (GBP)
Organisation Government of Scotland 
Department Scottish Funding Council
Sector Public
Country United Kingdom
Start  
 
Description Lifelong Health and Wellbeing Edinburgh Delerium Box
Amount £3,400,000 (GBP)
Funding ID G0700704/84698 
Organisation Medical Research Council (MRC) 
Department Lifelong Health and Wellbeing (LLHW)
Sector Public
Country United Kingdom
Start 02/2016 
End 01/2018
 
Description MRC Centenary Fund EDTB2 software based applications
Amount £25,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2012 
End 09/2013
 
Description MRC DCS (Functional Optical Imaging in mice and man)
Amount £2,357,633 (GBP)
Funding ID MR/J010901/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2013 
End 12/2015
 
Description MRC DPFS (Functional Optical Imaging in mice and man)
Amount £960,056 (GBP)
Funding ID MR/J014702/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2012 
End 08/2015
 
Description MRC/AZ(Functional Optical Imaging in mice and man)
Amount £250,000 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 12/2012 
End 12/2013
 
Description Maurice Wohl (A pharmacological pre-conditioning agent to reduce organ injury in transplantation)
Amount £50,000 (GBP)
Organisation The Royal College of Surgeons of Edinburgh 
Sector Learned Society
Country United Kingdom
Start 04/2012 
End 03/2015
 
Description NC3R MRC DPFS (Functional Optical Imaging in mice and man)
Amount £100,000 (GBP)
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Private
Country United Kingdom
Start  
 
Description Peri-operative Enhanced Recovery hip Fracture Care of patients with Dementia
Amount £1,960,000 (GBP)
Organisation Medical Research Council (MRC) 
Department MRC National Institute for Medical Research (NIMR)
Sector Public
Country United Kingdom
Start 04/2016 
End 02/2020
 
Description PhD Studentship (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs))
Amount £130,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description RSCEd Small Project Grant (A pharmacological pre-conditioning agent to reduce organ injury in transplantation)
Amount £7,000 (GBP)
Organisation The Royal College of Surgeons of Edinburgh 
Sector Learned Society
Country United Kingdom
Start 03/2012 
End 03/2013
 
Description SULSA-supported Scottish Hit Discovery Facility (SHDF) (TRPM8 agonists as analgesics for chronic neuropathic pain)
Amount £30,500 (GBP)
Organisation Scottish Universities Life Sciences Alliance 
Sector Academic/University
Country United Kingdom
Start  
 
Description Society of Endocrinology Early career Grant (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs))
Amount £10,000 (GBP)
Organisation Society for Endocrinology 
Sector Learned Society
Country United Kingdom
Start 05/2013 
End 04/2015
 
Description TENOVUS Small Research Grant (A pharmacological pre-conditioning agent to reduce organ injury in transplantation)
Amount £10,000 (GBP)
Organisation Tenovus 
Department Tenovus Scotland
Sector Charity/Non Profit
Country United Kingdom
Start 03/2012 
End 03/2013
 
Description mini project British Heart Foundation
Amount £1,500 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2016 
End 05/2019
 
Title Cell lines and assays (TRPM8 agonists as analgesics for chronic neuropathic pain) 
Description • Cell lines o TRPM8 o TRPV1 o TRPA1 • Assays o TRPM8 o TRPV1 o TRPA1 • In vivo animal models • Compound Library • Database of compounds and results • High throughput screen All these assets have been logged as Invention Disclosures within the University of Edinburgh Tech Transfer Office (Edinburgh Research and Innovation) 
Type Of Material Biological samples 
Year Produced 2009 
Provided To Others? Yes  
Impact SULSA screen at Dundee Hit Discovery Unit. Positive outcome. 
 
Title Cyclophilin isoform proteins (Cyclophilin inhibitors as anti-viral therapies) 
Description developed protocols to produce all medically important isoforms of the the cyclophilin family (CypA,B,C,D,) in milligram quantities 
Type Of Material Technology assay or reagent 
Year Produced 2010 
Provided To Others? Yes  
Impact expand potential discovery programmes for new cyclophilin indications. 
 
Title EDTB2 (New neuropsychological instrument for the diagnosis and monitoring of delirium 
Description The MRC DPFS grant funded the design and manufacture of the 'Edinburgh Delirium Test Box' version 2. Six devices were manufactured. Essentially the EDTB2 is seen as having the potential to make attentional deficits in delirium more measurable both in terms of detection of deficits, and severity grading. Measurement in delirium is acknowledged to be a priority area; there is no consensus on what outcome measures should be used in trials. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact We presented preliminary data from the EDTB2 at the European Delirium Association conference in Umea, Sweden, in Nov 2011. The EDTB1 and EDTB2 have attracted substantial attention, with two firm collaborations set up involving the EDTB2, and multiple other enquiries. 
 
Title EDTB2 (New neuropsychological instrument for the diagnosis and monitoring of delirium) 
Description Manufacture of 4 further devices for use in MSc and PhD projects and US collaborations. 
Type Of Material Technology assay or reagent 
Year Produced 2010 
Provided To Others? Yes  
Impact Continuing interest in measurement of delirium using the EDTB2 device and impact on clinical management 
 
Title EDULISS (Cyclophilin inhibitors as anti-viral therapies) 
Description The data-mining resource EDULISS (developed by Kun Yi Hsin and Steven Shave) is now freely accessible as a web-based resource (http://eduliss.bch.ed.ac.uk/test/ Nucleic Acids Res. 2011 : D1042-D1048) 
Type Of Material Technology assay or reagent 
Year Produced 2011 
Provided To Others? Yes  
Impact Two researchers associated with the programme further optimised EDULISS as part of ongoing research. A freely available tool should enhance SBDD projects. 
URL http://eduliss.bch.ed.ac.uk/test/
 
Title Fragment screening (Cyclophilin inhibitors as anti-viral therapies) 
Description protocols to enable fragment-based screening on crystals of the drug targets CypA, B and D and generated over 30 new structures for deposition in the PDB 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact this has provided unique insight into novel compounds leading towards achievement of LTP 
 
Title ICB-Morph (Cyclophilin inhibitors as anti-viral therapies) 
Description ICB-Morph; a software package for designing non-peptide analogues based on natural peptide ligands 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact NA 
 
Title Scaffold data base (Cyclophilin inhibitors as anti-viral therapies) 
Description ICB-SSCore; a database containing over 200 small molecular scaffold combinatorial chemistry libraries designed for bead-based synthesis giving approximately 10 trillion synthetic possibilities 
Type Of Material Biological samples 
Year Produced 2010 
Provided To Others? Yes  
Impact novel insights in other targets 
 
Title Sreening reagents (KMO Inhibitors) 
Description Multiple cell lines for use in drug screens have been generated. Off-target screening assays have been developed. High throughput screening assays have been developed. Refinements of disease models have been made for the assessment of efficacy in rodents. a new in vivo pharmacodynamic/pharmacokinetic model has been generated 
Type Of Material Technology assay or reagent 
Year Produced 2011 
Provided To Others? Yes  
Impact Manfred Auer Team Edinburgh GSK DPAc 
 
Title compound library (TRPM8 agonists as analgesics for chronic neuropathic pain) 
Description Library of over 50 compounds with extensive SAR including in vivo model assessment for best performing compounds 
Type Of Material Biological samples 
Provided To Others? No  
Impact supported validation of target and acceptance of tractability 
 
Title compounds (Cyclophilin inhibitors as anti-viral therapies) 
Description 10,500 compounds have been prepared that can probe the key site for inhibition of cyclophilin that will contribute to SBDD projects across cyclophilin targets. 
Type Of Material Biological samples 
Year Produced 2010 
Provided To Others? Yes  
Impact Approaching potency and selectivity target. 
 
Title new compounds to sense enzyme activity (Functional Optical Imaging in mice and man) 
Description 24 new compounds with diverse functions to sense enzyme activity in vivo for experimental models and man 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Selected compound will be tested in man as potential in vivo diagnosis for lung inflammation and potential treatments 
 
Title single molecule assay (Cyclophilin inhibitors as anti-viral therapies) 
Description A single molecule spectroscopic assay has been developed based on a fluorescently labelled high affinity cyclophilin binder providing a unique tool for miniaturised binding and competition studies. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Key technique for developing library screening approaches 
 
Title skin irritation and allergy and skin ultrasound (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)) 
Description in vivo methods developed and adapted for project 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Provided To Others? No  
Impact demonstrated significant efficacy for test material equivalent to standard of care with reduced side effects. 
 
Description A new paradigm for testing pathway tractibility in lung disease 
Organisation Medical Research Council (MRC)
Department MRC Mechanisms for disease call - Astra Zeneca
Country United Kingdom 
Sector Public 
PI Contribution University is developing new imaging agents
Collaborator Contribution AstarZeneca are providing valuable input
Impact too early
Start Year 2013
 
Description A novel topical anti-inflammatory agent -development with Therakind 
Organisation TheraKIND
Country United Kingdom 
Sector Private 
PI Contribution working up complex collaborative funding applications
Collaborator Contribution working up complex collaborative funding applications
Impact applications submitted
Start Year 2013
 
Description Alternative screening (KMO Inhibitors) 
Organisation University of Edinburgh
Department School of Biological Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution The DPFS research team have contributed the screening cascade
Collaborator Contribution Manfred Auer laboratory provides the application of miniaturised, ultra-high throughput screening platforms for the identification and validation of lead compounds for drug discovery and tool compounds for basic research. His "Integrated Chemical Biophysics" platforms (ICB) include in-silico design and screening, tagged one-bead one compound library production and screening on the surface of beads and chips, in solution, in cells and in model organisms. ICB platforms combine chemical, biological, and physical approaches to overcome many of the limitations of the current industrial early drug-discovery process
Impact Too early for comment
Start Year 2010
 
Description Astex (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) 
Organisation Astex Pharmaceuticals
Department Astex Therapeutics Ltd
Country United Kingdom 
Sector Private 
PI Contribution The DPFS team have evaluated the performance of the compound in detailled biochemical cellular and in vivo experiments
Collaborator Contribution Astex have provided clinical compound AT13387 for the project and all information contained in the Investigators Broachure
Impact We are now discussing how to develop an orphan drug application and clinical protocol.
Start Year 2009
 
Description DPFS Dell App 
Organisation Cambridge Cognition Ltd
Country United Kingdom 
Sector Private 
PI Contribution Edinburgh bring extensive basic and clinical experience in delirium testing both pen and paper, the Del Box and recently the Del App. The collaboration is supported by a DPFS grant.
Collaborator Contribution Cambridge Cognition develop and sell products for testing cognition primarily for AD.
Impact Join application for Biomedical Catalyst funding
Start Year 2016
 
Description DPFS Topical anti-inflamatory 
Organisation Queen Elizabeth Hospital Birmingham
Country United Kingdom 
Sector Hospitals 
PI Contribution providing compound and science 5?THB
Collaborator Contribution investigating mechanisms of 5?THB action in DUSP1 KO mice.
Impact too early
Start Year 2013
 
Description Debiopharm (Cyclophilin inhibitors as anti-viral therapies) 
Organisation Debiopharm
Country Switzerland 
Sector Private 
PI Contribution Debiopharm are active in the area of cylophilin inhibitors we are looking for novel chemistry and approaches.
Collaborator Contribution compound testing and intellectual contribution
Impact Debiopharm may be the exit for the project as the compounds generated are getting closer to LTP
Start Year 2009
 
Description Dundee SULSA Screen (TRPM8 agonists as analgesics for chronic neuropathic pain) 
Organisation University of Dundee
Department Division of Biological Chemistry and Drug Discovery
Country United Kingdom 
Sector Academic/University 
PI Contribution The team provided the TRPM8 cell based screen and work extensively with the partner in transfer and validation. Scottish Universities Life Sciences Alliance (SULSA) is a research pooling partnership between the Universities of Aberdeen, Dundee, Edinburgh, Glasgow, St Andrews and Strathclyde that is supported by the Scottish Funding Council.
Collaborator Contribution A library of 16,000 compounds was screened against the target identifying hits and new chemical scaffolds suitable for a medicinal chemistry programme
Impact The 'hits' from the screen have been validated in the Mitchell laboratory and 5 compounds have been identified as potential new lead compounds. Cell biologists -DPFS Edinburgh Screening technologists Dundee
Start Year 2010
 
Description EDTB2 ICU ERI (New neuropsychological instrument for the diagnosis and monitoring of delirium) 
Organisation Royal Infirmary of Edinburgh
Department Intensive Care Unit (ICU)
Country United Kingdom 
Sector Hospitals 
PI Contribution Provision of EDTB2 and expertise to enable a MHRA approved programme
Collaborator Contribution ICU consultants evaluated the device
Impact Clinical trial results
Start Year 2012
 
Description EDTB2 Iowa (New neuropsychological instrument for the diagnosis and monitoring of delirium) 
Organisation University of Iowa
Country United States 
Sector Academic/University 
PI Contribution We are providing EDTB2 as part of collaboration where we instigated interest in using our device for measuring delirium
Collaborator Contribution Setting up clinical collaborations, where EDTB2 will be provided at cost. This has propelled project to investigate and obtain appropriate approvals.
Impact NA
Start Year 2011
 
Description EDTB2 Johns Hopkins (New neuropsychological instrument for the diagnosis and monitoring of delirium) 
Organisation Johns Hopkins University
Department School of Medicine Johns Hopkins
Country United States 
Sector Academic/University 
PI Contribution Provision of EDT2
Collaborator Contribution Setting up clinical collaborations, where EDTB2 will be provided at cost. This has propelled project to investigate and obtain appropriate approvals. assisted with developing specification for product suitable for US use
Impact none
Start Year 2011
 
Description EDTB2 Pennsylvania (New neuropsychological instrument for the diagnosis and monitoring of delirium) 
Organisation University of Pennsylvania
Department Perelman School of Medicine
Country United States 
Sector Academic/University 
PI Contribution Introduced potential of EDTB2 for determination of Delirium
Collaborator Contribution Setting up clinical collaborations, where EDTB2 will be provided at cost. This has propelled project to investigate and obtain appropriate approvals. assisted with developing specification for product suitable for US use
Impact NA
Start Year 2011
 
Description EDTB2 Tablet PC (New neuropsychological instrument for the diagnosis and monitoring of delirium) 
Organisation NHS Greater Glasgow and Clyde (NHSGGC)
Department Medical Devices Unit
Country United Kingdom 
Sector Public 
PI Contribution Provision of EDTB2 device, supporting data and computer software.
Collaborator Contribution Developing a tablet PC-based software version of the EDTB2 tasks.
Impact First version complete. Pilot studies programmed for 2013
Start Year 2012
 
Description Eagle Designs (New neuropsychological instrument for the diagnosis and monitoring of delirium) 
Organisation Eagle Designs
Country United Kingdom 
Sector Private 
PI Contribution Clinical evaluation and practical utility of device designs
Collaborator Contribution Built on existing collaboration on version 1 of device to develop version 2 and contribution to patent application.
Impact The MRC DPFS grant funded the design and manufacture of the 'Edinburgh Delirium Test Box' version 2. Six devices were manufactured. For background: the 'Edinburgh Delirium Test Box' version 1 was designed and manufactured funded as part of an MRC Clinician Scientist Fellowship to AMJ MacLullich; this work resulted in a publication (Brown et al. J Neurol Neurosurg Psych 2011 Dec;82(12):1334-40; Epub in Jun 2010). This publication was the 'Patient's Choice' for that issue of the journal
Start Year 2008
 
Description GSK DPAc (KMO Inhibitors) 
Organisation GlaxoSmithKline (GSK)
Department Discovery Partnerships with Academia
Country Global 
Sector Private 
PI Contribution MRC DPFS support for our drug discovery activities has directly enabled the initiation a major industrial partnership with GSK as part of its Discovery Partnerships with Academia (DPAc) scheme. The collaboration is one of only ten to be awarded worldwide. MRC DPFS funding directly enabled the translation of fundamental biology into the role of a key metabolic enzyme in multiple organ failure and the subsequent discovery on novel enzyme inhibitors. This intellectual property forms the basis of the collaboration with GSK to develop new drugs for the treatment of multiple organ failure.http://www.edinburghbioquarter.com/news/2011/10/the-university-of-edinburgh-and-glaxosmithkline-gsk-agree-collaborative-partnership-for-drug-discovery.htm). The project has now completed its first milestone and is on course to fulfil the next milestone ahead of schedule. Update at Jan 2016, project has now passed clinical candidate selection point. The drug candidate is now in pre-clinical testing and is due to enter human clinical trials end 2018/early 2019.
Collaborator Contribution GSK will provide industrial strenght medicinal chemistry and screening and onwards into pre-clinical and clinical developemnt
Impact Further support for the CMVM Drug Discovery Unit http://www.edinburghbioquarter.com/news/2011/10/the-university-of-edinburgh-and-glaxosmithkline-gsk-agree-collaborative-partnership-for-drug-discovery.htm).
Start Year 2011
 
Description Mauna Kea Technologies Optical Equipment (Functional Optical Imaging in mice and man) 
Organisation Mauna Kea Technologies
Country France 
Sector Private 
PI Contribution Our research devloped the unique probes that will greatly enhance the clinical utility of Mauna Kea Technologies equipment. Other companies also provide/are developing similar technology so that we will have options for multiple routes to market
Collaborator Contribution Mauna Kea Technologies provide the optical equipment used to detect the probes in the lung.
Impact Probes tested in vivo in sheep lung using Mauna Kea Technologies equipment. Positive data obtained. formal partnership to develop a bespoke device for use with probes
Start Year 2010
 
Description Mechanism of AT13387 AB (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) 
Organisation University of Edinburgh
Department Centre for immunity, infection and evolution
Country United Kingdom 
Sector Academic/University 
PI Contribution EH brings expertise in renal transplatation
Collaborator Contribution Dr Amy Buck brings expertise in miRNA to the investigation of roll of AT13387 in organ protection
Impact research results on mechanism of action
Start Year 2012
 
Description Mechanism of AT13387 JH (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) 
Organisation University of Edinburgh
Department MRC Centre for Inflammation Research
Country United Kingdom 
Sector Public 
PI Contribution EH brings experience of renal transplant models and practice
Collaborator Contribution Prof Jeremy Hughes Dr David Kluth provide expertise in immunology
Impact data on mechanism of action of AT13387 in macrophages in AT13387 mediated renal protection
Start Year 2012
 
Description Medical Physics (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)) 
Organisation Royal Infirmary of Edinburgh
Department Intensive Care Unit (ICU)
Country United Kingdom 
Sector Hospitals 
PI Contribution novel approach to topical antiinflamatory medicine
Collaborator Contribution novel approach to analysis of inflammation using Ultra-sound
Impact in progress
Start Year 2012
 
Description PhD alternative screening (KMO inhibitors) 
Organisation University of Edinburgh
Department School of Biology
Country United Kingdom 
Sector Academic/University 
PI Contribution KMO inhibitor project bring a validated target and a screening cascade for the serious un-met need of acute pancreatitis
Collaborator Contribution The Auer laboratory are establishing novel platforms for bead based screening of directed libraries.
Impact New screening technologies have been developed and early identification of new inhibitors is in place.
Start Year 2011
 
Description Pig Model Development EC (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) 
Organisation University of Edinburgh
Department Royal School of Veterinary Studies
Country United Kingdom 
Sector Academic/University 
PI Contribution EH brings expertise in renal transplant to the vet school
Collaborator Contribution Professor Eddie Clutton provides porcine model
Impact research results
Start Year 2012
 
Description Pig Model Development RP (A pharmacological pre-conditioning agent to reduce organ injury in transplantation) 
Organisation University Medical Center Gronigen
Country Netherlands 
Sector Hospitals 
PI Contribution Expertise in the mouse renal transplant model
Collaborator Contribution EH is seconded to the post in the Netherlands at the moment, developing the pig model, which is directly related to this project and non-MRC funded.
Impact developemnt of the pig model of efficacy
Start Year 2011
 
Description SULSA (Cyclophilin inhibitors as anti-viral therapies) 
Organisation National Centre for Social Research
Department Scottish Centre for Social Research (ScotCen)
Country United Kingdom 
Sector Public 
PI Contribution Providing a cutting edge drug discovery project with novel stucture based drug design and screening approaches that were aligned to the setting up of the SULSA infrastructure
Collaborator Contribution Using 6 SULSA researchers over short projects 3-12 months key aspects of the project were advanced where they were aligned with the general skill infrastructure development of the SULSA team. this included library synthesis, medicinal chemistry, biophysical screening, virtual library design and spectroscopic assay design.
Impact This collaboration has allowed the project to attempt multiple approaches towards building peptidomimetics that would have been unavailable to the project under DPFS funding alone. The DPFS funding has been catalytic in harnesing other contributions. Additionally this included 2 contribution from 2 masters students.
Start Year 2009
 
Description Selcia (Cyclophilin inhibitors as anti-viral therapies) 
Organisation Selcia
Country United Kingdom 
Sector Private 
PI Contribution Structure based drug design
Collaborator Contribution Intellectual contribution to chemistry approaches
Impact Continuous provision of ultra high quality proteins
Start Year 2010
 
Description Ultra-sound measurements (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)) 
Organisation University of Edinburgh
Department Medical Physics & Medical Engineering Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration with Dr Carmel Moran, Medical Physics and Manager Ultra-sound facility.
Collaborator Contribution developing efficacy measure
Impact methods of efficacy detection using ultrasound as a method to measure skin thinning
Start Year 2011
 
Title 5alpha reduced metabolic breakdown products of glucocorticoids (Cyclophilin inhibitors as anti-viral therapies.) 
Description The present invention relates to the modulation of glucocorticoid metabolism. In particular the invention relates to the modulation of the functional activity of the glucocorticoid receptor by 5alpha reduced metabolic breakdown products of glucocorticoids 
IP Reference WO2003105838 
Protection Patent granted
Year Protection Granted
Licensed No
Impact The project has been able to demonstrate efficacy of the metabolite proposed in the patent. This will support a significant business proposition of granted patent and naturally circulating compound.
 
Title APPARATUS AND METHOD FOR TESTING SUSTAINED ATTENTION AND DELIRIUM (New neuropsychological instrument for the diagnosis and monitoring of delirium 
Description A testing apparatus for testing a user's sustained attention comprises at least one stimulus-providing means and a controller for controlling the stimulus providing means to provide at least one target stimulus, wherein the controller is configured to perform at least one operating procedure and the or each operating procedure comprises controlling the stimulus-providing means to provide a sequence of target stimuli to the user. 
IP Reference US2012271194 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact Commercial potential underpinned and consolidation with other attention devices under evaluation as a new spin out.
 
Title Optical imaging probes (Functional Optical Imaging in mice and man) 
Description Probes that will change wavelenght when subjecyed to enzymes in activated neutophiles. 
IP Reference GB1106004.3 
Protection Patent application published
Year Protection Granted
Licensed Yes
Impact A total of £10.51 million has been obtained in follow on funding and a company formed to develop the broad technology. A non exclusive collaboratoration deal is in place with Mauna Kea on development of bespoke equipment. The spin-out has an investment of £4M to commercialise the technology
 
Title Patent for (5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs)) 
Description The present invention relates to the modulation of glucocorticoid metabolism. In particular the invention relates to the modulation of the functional activity of the glucocorticoid receptor by 5a reduced metabolic breakdown products of glucocorticoids. 
IP Reference US20050130946 
Protection Patent granted
Year Protection Granted
Licensed No
Impact Has provided valuable commercial protection for this translational programme
 
Title TRPM8 INDUCTION OF ANALGESIA IN NEUROPATHIC PAIN (TRPM8 agonists as analgesics for chronic neuropathic pain) 
Description Use of known TRPM8 agonists including menthol for induction of analgesia in neuropathic pain 
IP Reference WO2008015403 
Protection Patent application published
Year Protection Granted
Licensed No
Impact The protection has supported the evaluation of a menthol gel for treatment of cancer induced neuropathic pain. The positive trial supports the selection of the TRPM8 programme as a fast follower to the menthol product
 
Title 5a-reduced glucocorticoids as selective glucocorticoid receptor modulators (SGRMs) 
Description "Glucocorticoids are amongst the most widely prescribed drugs but their use is limited by metabolic and bone adverse effects. We have identified endogenous anti-inflammatory glucocorticoids which lack some adverse effects. The lead compound is 5a- tetrahydrocorticosterone (5aTHB). We now aim to evaluate its efficacy in further models of inflammation and to detail its side-effect profile. More comprehensive proof-of-principle data will unlock follow-on funding to support "first in man" studies and optimise the lead drug, initially for topical use in skin disease. Specifically, 5aTHB will be studied: 1) Anti-inflammatory efficacy will be compared with hydrocortisone in murine models of skin inflammation and arthritis. 2) Pharmacokinetic parameters will be assessed in mice. 3) Metabolic, skin and bone toxicities will be compared to hydrocortisone at equivalent antiinflammatory doses in mice. Results will determine the potential of 5aTHB as topical and/or systemic therapy as a safer alternative to current first line therapy with conventional glucocorticoids. Most recent work supported by DPFS Portfolio Award" 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2011
Development Status Under active development/distribution
Impact tbc 
 
Title A pharmacological pre-conditioning agent to reduce organ injury in transplantation 
Description Despite great improvements in outcome following organ transplantation, the incidence of graft failure remains high. Our research focuses on developing pharmacological strategies to reduce ischemia/reperfusion injury (IRI), the main contributor to early graft failure. Our aim is improve the function and longevity of transplanted organs by administering a single dose of an agent to a multi-organ donor prior to organ retrieval. This would prime protective cellular mechanisms in anticipation of the injurious nature of ischemia, cold storage and reperfusion. We are investigating a number of candidate compounds at the molecular level and are studying the most promising in a mouse model of renal IRI. For instance, using heat shock protein 90-binding agents (HBA), we have demonstrated upregulation of protective heat shock proteins in the heart, lungs, liver and kidneys and shown a functional and morpholgical renal protection. We are now in a position to extend our research portfolio and examine these agents in a phase 1 trial. Intellectual Property protection: Patent GB0710781.6 (University of Edinburgh, June 2007, PCT: WO2008/149103) covers the use of KMO inhibitors in organ failure and methods of monitoring therapy. Most recent work supported by DPFS Portfolio Award and a collaboration with Astex Therapeutics. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2011
Development Status Under active development/distribution
Impact tbc 
 
Title Cyclophilin inhibitors as anti-viral therapies. 
Description Cyclophilin (CypA) is a target for HIV and HCV infection. The only pharmacologically useful molecules known to inhibit CypA are cyclopsporines (CsA). Non-immunosuppressive CsA analogues are showing promising in phase 2 clinical trials for HCV infection. Based on virtual screening and structural studies we have identified six different chemical scaffolds that inhibit cylophilin isomerise activity in the low micromolar range. Modelling studies show that with appropriate chemical derivitisation the scaffolds could be turned into lead compounds for drug development. We will design, synthesise and screen large bead-based libraries of compounds (thousands to hundreds of thousands, depending on SAR and building block availability). This approach will enable us to identify submicromolar binders and generate SAR binding data from primary screening. Viral screens will be carried out with our potential commercial partners (Debiopharm, Switzerland). Leads generated would represent first in class lmw non-peptide CypA inhibitors. Most recent work supported by DPFS Portfolio Award and included a collaboration with Debiopharm. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2011
Development Status Under active development/distribution
Impact Multiple new tools and approaches to SBDD established. 
 
Title DPFS Molecular Imaging 
Description Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs 
Type Diagnostic Tool - Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2014
Development Status Under active development/distribution
Clinical Trial? Yes
Impact company formed 
URL https://clinicaltrials.gov/show/NCT01532024
 
Title EDBT word building task 
Description We have also designed a new test implemented on the EDTB2 platform called the 'Word Building Task'. This is a new test of sustained attention which is essentially a verbal version of the EDTB2 counting tasks. It was the subject of an MSc project by Gemma Brown and the results of this study show that this new task is highly promising as a means of testing attention in patients with delirium. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2012
Development Status Under active development/distribution
Impact The work is being presented at the European Delirium Association meeting in October 2012 and will shortly be submitted for publication. 
 
Title EDTB2 ICU product 
Description We have also designed a new protocol which allows the use of the EDTB2 in ICU settings, where most patients are unable to communicate verbally because they are intubated. This was another MSc project. The results of this project were highly encouraging. We believe this is a significant step forward; it is the first computerised test of attention in delirium to be used in ICU settings, and (to our knowledge) the second formal evaluation of cognitive testing in delirium in ICU. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2012
Development Status Under active development/distribution
Impact The work is also being presented at the European Delirium Association meeting in October 2012 and will shortly be submitted for publication. 
 
Title EDTB2 software version 
Description In collaboration with NHS Greater Glasgow and Clyde we have produced the first software version of EDTB2. This is in the pilot phase of study at present. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2012
Development Status Under active development/distribution
Impact Will lead to an app version 
 
Title Edinburgh Delirium Test Box 
Description The Edinburgh Delirium Test Box work has led to a new collaboration with the Medical Devices Unit of NHS Greater Glasgow and Clyde (Alexander Weir and Stuart Parks). We produced a new software version of the Edinburgh Delirium Test Box attentional test. This new test is called the DelApp and is implemented on the Android smartphone platform (though it is also readily implementable on other software platforms, eg. iOS). 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2013
Development Status Actively seeking support
Impact With the help of Edinburgh Bioquarter we have now set up a new partnership with Cambridge Cognition with a view to commercialising the DelApp for use by healthcare practitioners. As part of this process we are applying for a DPFS grant (outline submitted in July 2013; full application invited and will be submitted by 20 Nov 2013). The University of Glasgow is also a partner in this application (Geriatric Medicine - Prof David Stott, Clinical Neuropsychology - Prof Jonathan Evans, Anaesthesia and Critical Care - Dr Tara Quasim). A collaboration has been formed with Cambridge Cognition and a grant secured from Biomedical Catalyst for its further development. 
 
Title GMP material for Functional Optical Imaging in mice and man. 
Description The project focus is on the generation of optical molecular soultions for the preclinical acdemic, preclinical pharmaceutical and clinical communities. The main focus will be on generating a probe to detect human neutrophil elastase and perform in first in man study in acute lung injury. Most recent work supported by DPFS Portfolio Award The project has recieved £2M funding from HICF to increase the range of probes and indications. The leading compound NAP has been made to GMP completed preclinical testing and is approved by MHRA for administration to man. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Refinement. Clinical
Year Development Stage Completed 2011
Development Status Under active development/distribution
Impact A product has been made to GMP called NAP. This product has passed preclinical toxicology and is undergoing formulation. A company Edinburgh Molecular Imaging is a the late stage of becoming a spin out. 
 
Title KMO Inhibitors 
Description We have discovered that small molecule inhibitors of kynurenine-3-monoxygenase (KMO) reduce the severity of acute pancreatitis (AP) associated multiple organ failure (MOF) in rats, and have robust evidence that the pathway is upregulated in human patients with AP. This project builds on a patent GB0710781.6 (University of Edinburgh, June 2007, PCT: WO2008/149103) that covers the use of KMO inhibitors in organ failure and methods of monitoring therapy. We have established a strong team-based collaboration between Clinician Scientists, Drug Discovery Core facility, Chemistry and potential commercialisation partners. The project has two arms; 1) will evaluate lead stage KMO inhibitors identified by Roche, 2) in parallel to building a screening cascade and developing a discovery programme using in silico screening and HTP screening towards the identification of distinct and novel lead series, using AP-MOF as the primary indication. Most recent work supported by DPFS Portfolio Award 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2011
Development Status Under active development/distribution
Impact A significant collaboration with GSK uder the DPAc scheme has been agreed that will take the project through to launch is all stages are successful. From advanced hit to launched compound a significant translational pathway. 
 
Title New neuropsychological instrument for the diagnosis and monitoring of delirium 
Description Delirium is a common (at least 1 in 8 hospital inpatients) and severe acute neuropsychiatric syndrome mainly affecting older hospital inpatients, characterised by acute cognitive decline. Delirium is associated with multiple adverse outcomes, and is extremely expensive: the 1-year economic burden in the USA was recently estimated at between $38BN and $152BN. Despite its clear importance, delirium is grossly underdiagnosed: around 50% of cases go undetected. A fundamental cause of this is that diagnosis depends on subjective rating scales, which have inadequate sensitivity, specificity and inter-rater reliability. Therefore, better tests for delirium are urgently required. We have recently built and piloted a new neuropsychological instrument for the objective diagnosis of delirium. It shows excellent sensitivity for inattention and discriminates between delirium and dementia. Here we propose to develop this instrument by building a second prototype and validating this in larger clinical populations. A validated instrument would have wide potential clinical and research utility. Most recent work supported by DPFS Portfolio Award 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Initial development
Year Development Stage Completed 2011
Development Status Under active development/distribution
Impact We are currently actively evaluating the route to market for this device. It is likely that it will be combined with an Alzheimer's disease test also developed in Edinburgh into a to be formed spinout company NeuroDx. 
 
Title TRPM8 agonists as analgesics for chronic neuropathic pain 
Description " We have unique insights into the analgesic potential of TRPM8 ion channel-containing nerves in the skin, having discovered that they can over-ride pain inputs to the central nervous system, thus acting as a 'master-switch' in particular types of nerve injury.We have established a productive medicinal chemistry programme with SE Proof of Concept funding (ending December 2009) based on small molecule agonists of TRPM8 and synthesised a novel series of drug like compounds (ca. 100). Ca. 20 members have low µM potency in vitro and 6 show analgesic efficacy in vivo by topical and/or intrathecal administration in an established rodent model of neuropathic pain. IP space is excellent, and we have successfully reached the goal we set out to achieve at the start of SE funding. We have two main aims: Firstly to achieve rapid expansion of SAR space around our lead series, while establishing optimal potency, selectivity and in vivo analgesic efficacy. This will bring us to a position, well placed to submit a strong composition of matter patent on novel TRPM8 agonists for the treatment of neuropathic pain. Secondly, and key to our medicinal chemistry efforts, will be the development of at least one back-up series of compounds that will significantly strengthen our overall IP position and de-risk the project. This is central to the long term funding of the project either through WT Seeding Drug Discovery awards (applied for Nov 09), or partnership with various pharma companies. Future Outcome: Partnership with pharma through NeurocentRx and building of value in the company. It should be noted that this programme is anticipated to complement a broader PAIN PROGRAMME, encompassing a clinical study validating the target and approach, with this project forming a fast follower product as typically seen in pharma pipelines. Together they provide for an attractive licensable package. Most recent work supported by DPFS Portfolio Award" 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2011
Development Status Actively seeking support
Impact The programme has achieved lead compounds active in animal models, and specific for target with a structure confirming that a lead optimisation programme would be expected to deliver a clinical candidate. 
 
Company Name SESMOS Ltd 
Description A spin-out company of the School of Biological Sciences which started operations on Oct 14, 2011. Investors and co-Founders are (a) Siemens Technology Accelerator, Munich (Germany), and (b) Scottish Enterprises. Company mission: SESMOS Ltd links the acoustic resonator CMOS technology developed at Siemens with the single bead & single molecule screening technology developed at the Auer lab. SESMOS Ltd is a life sciences company that develops a novel integrated screening and validation process for drug discovery. The core of our technology is based on miniaturized small molecule libraries and fully quantitative and quality controlled biophysical screening technologies from the University of Edinburgh, linked with an innovative label free biosensor chip technology from Siemens AG. The company has secured funding and management support from Siemens and Scottish Enterprise and is currently located in the College of Science and Engineering at the University of Edinburgh, Scotland. The next twelve months will see the development of the proprietary SESMOS process, integration and subsequent first commercial screens being completed. If you would like to contact us, please email b.collier@sesmos.com or visit our Linkedin page The company was dissolved in 2014. 
Year Established 2011 
Impact Delivering new chemical modulators for customer drug targets in a thoroughly quality controlled and quantitative process at lower costs compared to competition.
Website http://www.sesmos.com/
 
Company Name Edinburgh Molecular Imaging (Functional Optical Imaging in mice and man) 
Description EMI has been formed from the team that received a DPFS award. The academic team continue to build indications with multiple awards. Raised £4M to build the company. Founded in February 2014 by leading academics from the University of Edinburgh who developed a versatile and disease focused approach to Optical Tracer Development. The company will build multiple probes and applications for testing in models and man 
Year Established 2014 
Impact NA
Website http://www.edinimage.com/
 
Description BIO2010(TRPM8 agonists as analgesics for chronic neuropathic pain) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Biopartnering meeting with several Pharmaceutical and Biotechnology companies.

Identified key questions for inclusion in future presentations
Year(s) Of Engagement Activity 2010
 
Description BIO2011(TRPM8 agonists as analgesics for chronic neuropathic pain) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact BioPartnering meeting with Pharmaceutical and Biotechnology companies

Identifying increased interest as project has reached lead series and target is more accepted
Year(s) Of Engagement Activity 2011
 
Description BioTrinity 2011 (TRPM8 agonists as analgesics for chronic neuropathic pain) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Individual meetings with Pharma companies and investors

Awarenss of project and potential for company product.
Year(s) Of Engagement Activity 2011
 
Description EDTB2 2011-2012 MRC Annual Review 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact MRC Annual review widely distributed to policy makers and the public

none reported
Year(s) Of Engagement Activity 2012
 
Description International users conference of Cellvizio (Functional Optical Imaging in mice and man) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact The International Conference of Cellvizio® Users (ICCU) is a unique event taking place annually during which Cellvizio users can share their knowledge and findings, develop guidelines for pCLE and discuss new indications

Awareness of technology and project
Year(s) Of Engagement Activity 2011